EN DE
Watch Pangaea Oncology S.A. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Pangaea Oncology S.A. (PANG) fair value: what the stock is really worth

As of Oct 26, 2026: fair value (intrinsic value) of Pangaea Oncology S.A. stock €1.24, price €1.47, that is 15.6% below the price, quality 36 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare ES · ISIN ES0105221008

PO Pangaea Oncology S.A. logo Thin data Nov 10, 2026

Pangaea Oncology S.A.

PANG · MC
Expensive, weak quality

Our calculation puts a fair price 16% below what the stock costs today.

Low debt
Expensive Growth (revenue 5y +28.8 %/yr in EUR)
Fair value €1.24 · Overvalued
Quality 36/100
Loss-making · -24.8% net margin (TTM)
Negative free cash flow
Trails peers (2/10)
Narrow moat 14/100 · thin data
Thin data
Estimate⚠ Thinly traded
Watch Pangaea Oncology S.A. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

€2.66 €0.9559 Fair Value €1.24 Jun 2017 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range €0.9559 – €2.66 · fair‑value band €0.9300 – €1.54 · the €1.47 price screens above the €1.24 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 2 fiscal years are left out: there the valuation rested on only a fraction of the usual models. As of Nov 10, 2026.

Follow Pangaea Oncology in your weekly email

Every Wednesday you see whether Pangaea Oncology is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Pangaea Oncology, S.A., a medical services company, provides a range of services to cancer patients in Spain and the rest of European Union countries.

Show moreShow less

It offers molecular diagnostics, such as mutation analysis in tissue and liquid biopsy, gene amplification and translocation testing, immunohistochemistry and fluorescence in-situ hybridization, and gene expression profiling; clinical trials; in vitro drug profiling, including MTT proliferation assays, western blotting, colony formation, migration and invasion assays, and gene silencing; and Dx platform, which performs companion diagnostic platform validation.

The company also provides biomarker discovery to improve treatment through identification of novel theranostic biomarkers. Pangaea Oncology, S.A. was incorporated in 2006 and is based in Barcelona, Spain.

Stock analysis

Pangaea Oncology S.A. (PANG) currently trades at €1.47, while our estimate is €1.24, 16% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: €0.9300 (bear) to €1.54 (bull), the price of €1.47 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 36/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Pangaea Oncology S.A. reported revenue of €14.5M in FY2025 versus €4.6M in FY2021, a compound +33.3%/yr. Reported net income was −€3.6M in FY2025.

Key figures

Market cap €50.2M Micro · P/S ratio 3.63 · EPS (TTM) €−0.1100 · Net margin −24.8% · Return on equity −15.9% · Return on assets (EBIT) −1.6% (5-year average) · Operating margin −29.7% · Revenue (TTM) €14.5M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 14 out of 100 (low confidence).

What moves the price

The share trades about 16% below its 52-week high and 3% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −11% fair-value upside, at −16%, PANG screens richer than that median.

Fair Value

Bear €0.9300 Fair Value €1.24 Bull €1.54
Price €1.47 · Downside -15.6%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 36/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 22
How much profit the company makes from its sales and capital
Quality Growth 24
Are margins and returns getting better?
Cashflow 5
Do the profits arrive as real cash?
Financial strength 72
Debt, balance sheet and risk of trouble
Investment 91
Does it invest with discipline instead of growing at any price?
Low Volatility 94
How calm the share price moves, does not count
Price momentum 29
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 14
Distance to the 52-week high, does not count
New shares 22
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+1.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+49.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+28.8%
Start year 2020 (pandemic). Over 10 years: +22.2% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.8%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−40.6% (2020) → −25.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

PANG screens overvalued: fair value 16% below the price. Compare with Thermo Fisher Scientific Inc →

Compare Pangaea Oncology S.A. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 149 stocks

Beats the industry median on 2/9 measures
Overall it trails its industry peers.
Valuation
Quality Score 36 · Bottom 25%
Fair Value upside −15.6% · Above median
Profitability
Return on assets −11.2% · Below median
Net margin (12 months) −24.8% · Bottom 25%
Operating margin (12 months) −29.7% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −5.2% · Bottom 25%
Balance sheet
Debt / equity 0.10× · Below median

Valuation Multiplesvs Diagnostics & Research median · lower = cheaper

P/B 2.36× · Pricier than median
P/S (12 months) 3.46× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)13 · sector 12
FUTURE (revenue growth)0 · sector 40
PAST (return on equity)0 · sector 7
HEALTH (low debt)95 · sector 95
DIVIDEND (yield)0 · sector 32

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
WuXi AppTec Co 603259 ¥150.30 ¥165.32 +10% vs PANG
Illumina, Inc ILMN $214.91 $234.44 +9% vs PANG
IQVIA Holdings IQV $275.15 $299.58 +9% vs PANG
Thermo Fisher Scientific Inc TMO $718.20 $686.04 −4% vs PANG
Danaher Corporation DHR $236.11 $209.18 −11% vs PANG
IDEXX Laboratories, Inc IDXX $696.64 $496.48 −29% vs PANG
Mettler-Toledo International Inc MTD $1,751 $655.06 −63% vs PANG
Agilent Technologies, Inc A $177.88 $64.53 −64% vs PANG
Lonza Group LONN CHF 661.00 CHF 153.50 −77% vs PANG
Waters Corporation WAT $475.52 $91.26 −81% vs PANG

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Pangaea Oncology S.A.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Pangaea Oncology S.A. Fair Value". https://www.fairvalue-calculator.com/stock/PANG

Frequently asked questions

Is Pangaea Oncology S.A. (PANG) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is €1.24 versus the last price from Oct 26, 2026 of €1.47, about 16% lower (overvalued).
What is the fair value of PANG?
Our estimate for Pangaea Oncology S.A. is €1.24 (as of Nov 10, 2026), built from audited fundamentals. Last price (from Oct 26, 2026): €1.47.
What is the quality score of PANG?
Pangaea Oncology S.A. has a Quality Score of 36/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Pangaea Oncology S.A. (PANG)?
Our calculated price target is the estimate of €1.24 (as of Nov 10, 2026). Cautious scenario €0.9300, optimistic scenario €1.54. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Pangaea Oncology S.A. stock forecast for 2026?
Our estimate puts fair value at €1.24, about 16% lower versus the last price from Oct 26, 2026 of €1.47 (overvalued). Cautious scenario €0.9300, optimistic scenario €1.54. The calculation is refreshed regularly with new filings.
What is the revenue of Pangaea Oncology S.A. (PANG)?
Pangaea Oncology S.A. reported trailing-twelve-month revenue of about €14.5M (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Pangaea Oncology S.A. (PANG)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Pangaea Oncology S.A. it is €1.24 per share (as of Nov 10, 2026), against a price of €1.47.
Is Pangaea Oncology S.A. stock overvalued or undervalued in 2026?
As of Nov 10, 2026, PANG trades above its calculated fair value: price €1.47, fair value €1.24, a gap of about −16% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PANG?
No. The price is what the market pays today (€1.47); the fair value is what the company's own numbers justify (€1.24). For Pangaea Oncology S.A. the two are €0.2300 per share apart. That gap is exactly why we show both numbers side by side.
How much is Pangaea Oncology S.A. worth?
The market values Pangaea Oncology S.A. at about €50.2M (market capitalisation, as of Nov 10, 2026). Per share that is €1.47; our models calculate a fair value of €1.24 per share.
What do the bullish and bearish scenarios say about PANG?
Our models span a range for Pangaea Oncology S.A.: cautious scenario €0.9300, base €1.24, optimistic €1.54 per share (as of Nov 10, 2026, price €1.47). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Pangaea Oncology S.A. (PANG)?
Balance-sheet figures for Pangaea Oncology S.A. (as of Nov 10, 2026): return on equity −15.9%, debt of 0.10 per unit of equity. They feed the Quality Score of 36/100, which measures business quality independently of the share price.
How far is PANG from its 52-week high?
Pangaea Oncology S.A. trades at €1.47, about 16% below its 52-week high of €1.75 and 3% above the low of €1.43 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of €1.24 is for.
Which stocks are comparable to Pangaea Oncology S.A.?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, IDEXX Laboratories, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Pangaea Oncology S.A. stock attractive at the current price?
The data as of Nov 10, 2026: price €1.47, calculated fair value €1.24 (−16%), Quality Score 36/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Pangaea Oncology S.A. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Pangaea Oncology S.A. (PANG)?
The latest price we hold is from Oct 26, 2026 and stands at €1.47. Our estimate is €1.24, about 16% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Pangaea Oncology S.A. right now?
Weak quality (36/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Pangaea Oncology S.A.

How large is the market capitalisation of Pangaea Oncology S.A. (PANG)?
The market capitalisation of Pangaea Oncology S.A. is €50.2M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Pangaea Oncology S.A. (PANG)?
The price-to-sales ratio of Pangaea Oncology S.A. is 3.63 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Pangaea Oncology S.A. (PANG)?
Earnings per share at Pangaea Oncology S.A. are €−0.1100. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Pangaea Oncology S.A. (PANG)?
The net margin of Pangaea Oncology S.A. is −24.8% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Pangaea Oncology S.A. (PANG)?
The return on equity (ROE) of Pangaea Oncology S.A. is −15.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Pangaea Oncology S.A. (PANG)?
On an EBIT basis the return on assets of Pangaea Oncology S.A. is −1.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Pangaea Oncology S.A. (PANG)?
The operating margin of Pangaea Oncology S.A. is −29.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Pangaea Oncology S.A. (PANG)?
Revenue at Pangaea Oncology S.A. is growing −5.2% versus a year earlier (3y avg +49.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Pangaea Oncology S.A. (PANG) generate?
The free cash flow of Pangaea Oncology S.A. is −€3.0M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Pangaea Oncology S.A. (PANG) carry?
The net debt of Pangaea Oncology S.A. is €3.8M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Pangaea Oncology S.A. in the live analysis

One click puts Pangaea Oncology S.A. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.